Evolus Q4 Preliminary Revenue Improves, Expects Revenue Growth In 2025; Pre-Market Stock Up Over 16%

Evolus

13.60 EUR -0.73%

• Charts
• News
• Analysen

Kaufen / Verkaufen

(RTTNews) - Evolus, Inc. (EOLS), a performance beauty company, on Tuesday reported a rise in preliminary revenue for the fourth quarter, driven primarily by higher volumes and market share gains.

David Moatazedi, CEO of Evolus, said: "The preliminary results for the fourth quarter and full-year 2024 underscore the strength of our operational execution and significant market share gains, driven by deeper penetration of the U.S. neurotoxin market with Jeuveau and international expansion of Nuceiva."

For the three-month period to December 31, 2024, the company posted revenue of $79 million, up 30 percent from the same period last year. For the full year, revenue stood at $266.3 million, up 32 percent from the prior year.

Looking ahead, for the full-year 2025, the company expects revenue of $345 million to $355 million, which represents 30 percent to 33 percent growth from preliminary full-year 2024 results.

Evolysse and Estyme injectable HA gels are anticipated to contribute 8 percent to 10 percent of total revenue for the full-year 2025.

EOLS was up by 16.08 percent at $12.20 in the pre-market trade on the Nasdaq.